An experimental skin cream developed by Rubedo Life Sciences shows promise in reducing biological age and improving skin conditions, according to early trial results.
Rubedo Life Sciences, a biotechnology company based in Mountain View, California, has announced promising preliminary data from an early human trial of its experimental skin cream, RLS-1496. The cream is reported to have cleared senescent cells, boosted collagen levels by 10%, and reduced skin age in a four-week study involving patients with eczema and other skin conditions.
In an analysis of 11 paired skin samples from individuals with atopic dermatitis, researchers found that four weeks of treatment was associated with an average decrease of 2.1 years in measured epigenetic skin age. This estimate is based on age-related changes in DNA.
Dr. Frederick Beddingfield, CEO of Rubedo, emphasized the significance of these early findings, stating they warrant further investigation. “This is one of the few drugs developed for aging in general and with AI to show positive data in humans in multiple indications and to show a reduction in skin age,” he told Fox News Digital. He expressed optimism that these initial results could lead to clinical improvements with longer-term treatment.
The findings regarding skin aging were presented at a scientific conference but have not yet been published in a peer-reviewed journal. RLS-1496 is designed to target senescent cells, which are aging or damaged cells that have ceased to divide but can release substances that promote inflammation. The drug specifically targets a protein called GPX4, which plays a role in how cells respond to stress. Researchers are investigating whether blocking this protein can help eliminate damaged, aging cells while allowing healthier cells to survive.
Beddingfield described this approach as focusing on cellular aging rather than merely addressing its visible effects. “It’s a bit like ‘what does not kill you makes you stronger’ for those surviving cells,” he added.
The skin samples analyzed in the study showed a 10% increase in a type of collagen that supports skin structure. Additionally, blood tests indicated lower levels of several markers associated with inflammation, although the implications of these changes for patient health remain unclear.
However, the preliminary findings come with limitations. The skin-aging analysis was based on just 11 paired samples, and it measured biological signs of aging rather than assessing whether the skin appeared younger or functioned better. The treatment duration of four weeks raises questions about the longevity of the observed changes. Furthermore, the studies were sponsored by Rubedo, and the findings have not yet undergone peer review.
Looking ahead, Beddingfield noted, “Our next trial will treat for several months.” The treatment is also being evaluated for other skin issues. In a separate early-stage study involving 22 patients with actinic keratosis—rough, precancerous skin patches caused by sun exposure—the company reported a 49% average reduction in lesions after 28 days of treatment. This open-label study compared treated forearms with untreated forearms rather than using a placebo cream.
According to Rubedo, the cream caused minimal skin irritation, and the drug was detected in the blood of very few participants. “With topical application, we have seen very little risk,” Beddingfield stated. “Local irritation is rarely seen and generally mild when it occurs, and no one has discontinued treatment to date. Very few subjects show any drug in their blood after skin application.”
Rubedo is also initiating an early-stage trial of RLS-1496 for androgenetic alopecia, commonly known as pattern hair loss. Beddingfield estimated that potential FDA approval for the treatment could be three to four years away, pending the results of larger clinical trials.
These developments highlight the ongoing research into innovative treatments for skin aging and related conditions, with the potential to significantly impact dermatological health in the future, according to Fox News Digital.